International Journal of Pathogen Research

Volume 13, Issue 5, Page 70-80, 2024; Article no.IJPR.123234
ISSN: 2582-3876

Genomic Investigation of *bla-PAO* and *bla-OXA50* in Multidrug-Resistant *Pseudomonas aeruginosa* from Clinical Samples in Abeokuta, Ogun State, Nigeria

Nimotalahi Omotunde [a], Olusola Abiodun Akingbade [b], Babatunde O. Motayo [a*], Paul A. Akinduti [c], Waliu Alabi Adeyemo [d] and Habibah Abosede Adebanjo [e]

[a] *Department of Medical Microbiology, Federal Medical Centre, Abeokuta, Ogun State, Nigeria.*
[b] *Department Medical Laboratory Science, Chrisland University, Abeokuta, Ogun State, Nigeria.*
[c] *Department of Biological Sciences, Covenant University Ota, Nigeria.*
[d] *Department of Chemistry Sciences, Federal University of Agriculture, Abeokuta, Nigeria.*
[e] *Department of Chemical Pathology, Federal Medical Centre, Abeokuta, Ogun State, Nigeria.*

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: https://doi.org/10.9734/ijpr/2024/v13i5311

Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here:
https://www.sdiarticle5.com/review-history/123234

Original Research Article

Received: 22/07/2024
Accepted: 24/09/2024
Published: 27/09/2024

**Corresponding author: Email: babatundemotayo@yahoo.com;*

Cite as: *Omotunde, Nimotalahi, Olusola Abiodun Akingbade, Babatunde O. Motayo, Paul A. Akinduti, Waliu Alabi Adeyemo, and Habibah Abosede Adebanjo. 2024. "Genomic Investigation of Bla-PAO and Bla-OXA50 in Multidrug-Resistant Pseudomonas Aeruginosa from Clinical Samples in Abeokuta, Ogun State, Nigeria". International Journal of Pathogen Research 13 (5):70-80. https://doi.org/10.9734/ijpr/2024/v13i5311.*

ABSTRACT

Pseudomonas aeruginosa is one of the pathogens of human concern with high intrinsic multi-drug resistance capabilities. The genomic investigation of blaPAO and blaOXA-50 was done on multi drug-resistant *Pseudomonas aeruginosa* that were also resistant to carbapenem among the isolates collected from a total of 128 clinical samples in Abeokuta, Nigeria. *Pseudomonas aeruginosa* isolates were obtained from pure culture, and profiled for antibiogram by disc diffusion method. Genomic DNA from isolates were typed for blaPAO and blaOXA-50 with PCR. A total of 75 samples (58.6%) yielded the growth of bacterial isolates. Bacteria isolated were *Escherichia coli* (18.8%), *Klebsiella pneumoniae* (16.4%), *Staphylococcus aureus* (8.6%), *Pseudomonas aeruginosa* (7.8%), *Streptococcus pnuemoniae* (3.1%), *Proteus mirabilis* (2.3%), and *Enterobacter aerogenes* (1.6%). Only ten (30%) isolates were confirmed to be *Pseudomonas aeruginosa*. All the *P. aeruginosa* isolates were resistant to ampicillin, cloxacillin, erythromycin, and tetracycline. Out of these ten multidrug *Pseudomonas aeruginosa* isolates, only three (30%) were resistant to carbapenems. Only two of these isolates expressed blaOXA-50 and blaPAO, while one possessed only blaPAO. Close Continuous monitoring of these antibiotic-resistant pathogens and hospital surveillance needs to be adopted to reduce their spread to other healthcare facilities.

Keywords: Pseudomonas aeruginosa; antibiotic resistance; blaPAO; blaOXA-50.

1. INTRODUCTION

Pseudomonas aeruginosa is one of the most common pathogens isolated from patients who have been hospitalized longer than one week and it is a leading cause of nosocomial infections in hospital settings and death cases have also been reported [1]. *P. aeruginosa* are ubiquitous and are found in several environmental niche and can spread to patients and healthcare providers in clinical settings particularly when exposed to contaminated clinical instruments, surfaces, beddings, water or soil. There is high risk of infection with patients on ventilators or other medical devices such as intravenous catheters [2]. Nosocomial *P. aeruginosa* infection include bloodstream infection, pneumonia, urinary tract infections and surgical wound infection. These infections mostly affect hospitalized patients especially those with weak immune systems and those on long term treatments [3]. *P. aeruginosa* has been recognized to have survival and adaptation abilities in a wide range of environments such as soil, water, sewage and hospitals [4]. Despite therapy the mortality due to nosocomial is approximately 70%, *P. aeruginosa* develops resistance to most of antibiotics thereby preventing the selection of appropriate treatment [5]. "Multi Drug Resistant *P. aeruginosa* (MDRPA) is a condition that bacteria resistant to three or more classes of antibiotics such as penicillins, cephalosporins, monobactam, carbapenem, aminoglycosides and fluoroquinolones. Inappropriate antibiotics administration can cause *P. aeruginosa* resistant to several classes of antibiotics" [6,7]. "*P. aeruginosa* nosocomial infections is generally difficult to treat because of the possibility intrinsic resistance and its ability to obtain faster resistance mechanism against many groups of antimicrobials" [8].

"Pseudomonas aeruginosa are both invasive and toxigenic bacteria and has become increasingly recognized as an emerging opportunistic pathogen of clinical relevance" [9]. "This organism has been incriminated in cases of meningitis, septicaemia, pneumonia, ocular and burn infections" [10]. "Wound infections related to burn patients often leads to bacteraemia. Different conditions such as severe neutropenia, mucosal ulcers, and malignancies lead to a risk for bacteraemia" [11,12]. "*Pseudomonas aeruginosa* is most commonly found in cystic fibrosis patients. The abnormal airway epithelia of these patients allow long-term colonization by this bacterium and, once they get infected, they rarely fade away and lead to chronic lung diseases" [13]. **"***Psuedomonas. aeruginosa* possess various *virulence* genes that contribute to its pathogenicity such as exotoxin The blaOXA -50 gene (formerly known as the PA5514 gene) is an oxacillinase gene identified in Sicily in the genome of Pseudomonas PAO1 isolate" [14]. "It has been reported that blaOXA – 50 naturally exists in all *P. aeruginosa* and does not appear to have been acquired based on the similar GC% content of the blaOXA – 50 gene to the overall *P. aeruginosa* genome" [15]. "Carbapenems are β-lactam antibiotics that consist of a four-membered β-lactam ring fused with a secondary

five-membered thiazolidine ring through the nitrogen and adjacent tetrahedral carbon atom. Unlike other β-lactams, carbapenems have two substitutions, at position one there is a substitution of sulfur for a carbon atom and at the fourth position of the thiazolidinic moiety, a carbon is substituted for a sulfone" [16-18]. The aim of our current study is to investigate the prevalence of muti-drug resistance *P. auereginosa* possessing the beta lactamase bla-OXA-50 and blaPAO1 genes isolated from clinical samples in Abeokuta, Ogun State.

2. MATERIALS AND METHODS

2.1 Sampling, Isolation and Identification

One hundred and twenty-eight clinical samples from Federal Medical Centre, Abeokuta, in southwest Nigeria were analyzed between June 2023 and January 2024. *P. aeruginosa* isolates obtained from the clinical samples were preserved in semi-solid Brain Heart Infusion (BHI) (Oxoid, Basingstoke, UK) supplemented with glycerol and re-characterized for confirmation following standard biochemical methods previously described [19].

2.2 Antimicrobial Susceptibility

The susceptibility profile of antibiotics commonly prescribed for *Pseudomonas aeruginosa* infections was determined using Kirby-Bauer disc diffusion in accordance with CLSI recommendations and guidelines [20,21]. Overnight culture from cetrimide agar was sub-cultured on BHI and further incubated for 24 h at 37 ◦C. Bacterial suspension of 0.5 MacFarland turbidity was spread on BHI using sterile swab stick. Twelve different antibiotics with different disc concentrations, such as Gentamycin (Gen) 10 µg/disc, Erythromycin (Ery) 15 µg/disc, Ceftriaxone (Cef) 30 µg/disc, Imipenem (Imp) 10 µg/disc, Meropenem (Mem) 10 µg/disc, Tetracycline (Tet) 30 µg/disc, Cefuroxime (Str) 30 µg/disc, Cloxacillin 30 µg/disc (Cxc), Ampicillin (Amp), 30 µg/disc, Cefuroxime (Cxm) 30 µg/disc, Ceftazidime (Caz) 30 µg/disc, Cefepime (Cef) 30 µg/disc and Ciprofloxacin (Cip) 5 µg/disc were used in this study. The antimicrobial sensitivity test of each isolate was carried out as described by the Kirby-Bauer disc diffusion method. The turbidity of the bacterial suspensions was compared with 0.5 Macfarland's barium sulfate standard solution. The standardized bacterial suspension was inoculated on Muller Hinton Agar (Lab M Laboratories, Mumbai, India) and left to dry for 10 minutes before placing the antimicrobial sensitivity discs. Antibiotic-impregnated discs of 8 mm in diameter were used for the test. After incubation, the diameter of the zone of inhibition was measured and compared with the zone diameter interpretative chart [20, 21] to determine the sensitivity of the isolates to antibiotics. The standard strain, *P. aeruginosa* ATCC 27853, was used as a control. Isolates showing resistance to at least one agent in more than three classes of the antibiotic group were classified as multi-drug resistant *P. aeruginosa* (MDR P. aeruginosa) according to Magiorakos et al. [22]. Multi antibiotic resistance index (MARI), was calculated for each isolated tested, using the formula below

MARI = No of resistant antibiotics ÷ Total number of antibiotics tested

2.3 Chromosomal DNA Extraction

Purified genomic bacterial DNA was extracted from overnight cultures of the three multidrug-resistant *Pseudomonas aeruginosa* isolates after growth on Tryptic Soy agar (TSA) medium using a genomic DNA mini kit (QIAGEN, QIAamp®, USA) according to the manufacturer's instructions. This serves as the template DNA. The concentration of the eluted DNA was measured using a NanoDrop 2000 spectrophotometer.

2.4 Polymerase Chain Reaction

The pure DNA of each of the three different *Pseudomonas aeruginosa* was subjected to the polymerase chain reaction (PCR), with the genes blaPAO and blaOXA-50 being targeted. The PCR reaction was performed with primer sets blaPAO forward F-TGCCTGGTAG TGGGGGATAA, reverse F-TGCCTGGTAGT GGGGGATAA, and blaOXA50 forward F-AATCC GGCGCTCATCCATC reverse R: GGTCGGC GACTGAGGCGG a total volume of 50 µL, containing 25 ng of DNA template, 10 mM Tris-HCl, 50 nmol KCl, 1.5 mM MgCl2, 200 µM dNTP (Fermentas), 12.5 pmol of each primer, 1 U Taq DNA polymerase (Fermentas), and 5 µL PCR buffer 10X. Reactions were initiated at 1 cycle at 94° for 3 min, followed by 30 cycles at 94°C for 30 s, 55 for 1 min, 72°C for 1.5 min, and a final elongation step at 72°C for 5 min [23].

2.5 Agarose Gel Electrophoresis

"Powdered agarose (0.8% w/v) was boiled in tris-acetic EDTA (TAE) buffer intermittently until the solution became a clear gel. The agarose solution was allowed to cool to 45°C before 7 µl

of ethidium bromide was added. The clear gel solution was poured into the gel tray with the comb in place and allowed to solidify. Thereafter, the gel tray and the comb were removed. The gel was placed into the tank containing TAE buffer. Then, 2µl of the tracking dye (bromophenol blue) was mixed with 1µl of 1.5 kb DNA ladder and loaded into the first well. Thereafter, 20µl of the bromophenol blue with 20µl of the sample was mixed and loaded into other wells. The cover of the tank was carefully placed on it and plugged into the power source to run from a negative to a positive direction, making sure it did not run a distance of far more than ¾ of the gel for approximately 30 minutes. Then, the gel was viewed via the UV transilluminator" [24]. A 1.5kb standard DNA molecular weight marker (Gene Mate, UK) was used in the study [25].

2.6 Data Analysis

The results were analyzed using descriptive Statistical methods. Graphs were generated with the libraries ggplot2; Rcolorbrewer and pheatmap in R-studio (www.rcoreteam). The dendogram was generated un DendroUPGMA software using the MARI scores of the isolates to generate a similarity matrix for the dendrogram construction. The subsequent tree was visualized in TVBOT (https://www.chiplot.online/tvbot.html).

3. RESULTS

From a total of 128 clinical samples were collected in this study; 75 (58.6) had the growth of bacteria (Table 1). Bacteria isolated were *Escherichia coli* (24), *Klebsiella pneumoniae* (21), *Staphylococcus aureus* (11), *Pseudomonas aeruginosa* (10), *Streptococcus pnuemoniae* (4), *Proteus mirabilis* (2), and *Enterobacter aerogenes* (2), which constituted 18.8%, 16.4%, 8.6%, 7.8%, 3.1%, 2.3%, and 1.6%, respectively (Table 2). The distribution of *Pseudomonas aeruginosa* isolates from the different clinical samples in relation to sex and age is shown in Table 3. Age groups 21–30 years, 51–60 years, and 61–70 years had 0.8% *P. aeruginosa* occurrence, respectively, while age groups 11–20 years and 31–40 years had 1.6% *Pseudomonas aeruginosa* occurrence, respectively.

The resistance pattern of the *P. aeruginosa* isolated from clinical samples to antibiotics showed that all the *P. aeruginosa* isolates identified were resistant to 4 of the antibiotics used namely; ampicillin, cloxacillin, erythromycin and tetracycline respectively, and had 30% resistant to imipenem and meropenem respectively (Fig. 1). The multi-drug-resistant *P. aeruginosa* isolates (n=3, 30%) were resistant to carbapenem. The result revealed that one of the *P. aeruginosa* isolates was resistant to seven classes of antibiotics, while three were resistant to six classes. Antibiotic resistance related was investigated using dendroUPGMA and the isolates clustered into 2 clades based on their MARI scores (Fig. 2a), both clusters harbored positive PCR positive ESBL isolates. Fig. 2b shows a heatmap containing antibiotic resistance profiles of the isolates according to the classes of antibiotics tested, including the bla-OXA50 and bla-PAO positivity rates of the isolates tested. From the heat map majority of the isolates were fully susceptible to carbapenem and quinolonce class of antibiotics while the chephalosporins class showed the highest resistance rates (Fig. 2b). Fig. 3 shows the Agarose gel pictures of the PCR reactions, showing positive bla-PAO bands of 180bp seen in multi-drug-resistant *P. aeruginosa w*hile plate 2 showed the bla-OXA50 bands of 700bp seen in the multi-drug resistant *P. aeruginosa.*

Table 1. Distribution of bacteria growth among clinical samples

Samples	No. of samples (%)	No. of yielded growth (%)	No culture growth (%)
Urine	58(45.3)	36(28.1)	22(17.2)
Wound swab	22(17.2)	11(8.6)	11(8.6)
Sputum	20(15.6)	12(9.4)	8(6.3)
Pus	15(11.7)	7(5.5)	8(6.3)
Ear swabs	8(6.3)	6(4.7)	2(1.6)
Burns	5(3.9)	3(2.3)	2(1.6)
Total	128(100.0)	75(58.6)	53(41.4)

Table 2. Percentage of occurrence of bacterial isolates in the clinical samples

Isolates	n = 128	Number (%) of bacterial isolates
Escherichia coli		24(18.8)
Klebsiella pnuemoniae		21(16.4)
Pseudomonas aeruginosa		10(7.8)
Staphylococcus aureus		11(8.6)
Streptococcus pneumoniae		4(3.1)
Proteus mirabilis		3(2.3)
Enterobacter aerogenes		2(1.6)
Total		**75(58.6)**

Key: n represents total number of clinical samples, %; represents percentage

Table 3. Distribution of *Pseudomonas aeruginosa* isolated from clinical samples in relation to sex and age

Sex	Total examined n (%)	Number (%) yielded growth of *Pseudomonas aeruginosa*
Male	55(42.9)	4(3.2)
Female	73(57.1)	6(4.6)
	128(100)	10(7.8)
Age group		
<u><</u>10	12(9.4)	0(0.0)
11 – 20	6(4.6)	2(1.6)
21 – 30	34(26.6)	1(0.8)
31 – 40	28(21.9)	2(1.6)
41 – 50	22(17.2)	3(2.3)
51 – 60	18(14.1)	1(0.8)
61 – 70	14(10.9)	1(0.8)
<u>></u> 71	4(3.1)	0(0.0)
Total	**128(100)**	**10(7.8)**



Fig. 1. Bar chart showing antibiotic resistance distribution among the various antibiotics tested against *Pseudomonas aeruginosa* isolated from patients in Abeokuta, Nigeria



Fig. 2a. Dendogram showing the antimicrobial based clustering and relatedness, showing, MARI scores and ESBL-PCR positivity



Fig. 2b. Heatmap showing resistance profiles of the *Pseudomonas aeruginosa* isolates against the different classes of antibiotics

4. DISCUSSION

"Pseudomonas aeruginosa is a versatile bacterium that causes a wide range of severe opportunistic infections in patients with serious underlying medical conditions. The prevalence of *Pseudomonas aeruginosa* in this study was 7.8%. *Pseudomonas aeruginosa* is currently one of the most frequent nosocomial pathogens, and infections due to this organism are often difficult to treat due to antibiotic resistance" [26]. All the *P. aeruginosa* isolates were completely resistant to ampicillin, cloxacillin, erythromycin, and tetracycline. This finding was in agreement with Akingbade et al. [27], who reported that "*P. aeruginosa* was 90% resistant to ampicillin and cloxacillin in south-west Nigeria". According to Juan et al., [28] "*P. aeruginosa* is the third most prevalent bacterium identified from infections contracted in intensive care units and is the main cause of morbidity and death in people with Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD), diabetes, and severe kidney and liver failure". "Hospital and community *Pseudomonas aeruginosa* infection control could suffer major setbacks due to high-level resistance to cell wall biosynthesis inhibitors (particularly Augmentin, ceftazidime and

ampicillin) which are most prescribed antibiotics" [29].

"All ten *Pseudomonas aeruginosa* isolates were resistant to three or more classes of antibiotics, and their multidrug patterns cut across all the commonly used drugs prescribed in the clinical setting. This is also consistent with other findings from Egypt" [30]. The spread of these antibiotic-resistant *P. aeruginosa* strains is increasing within the hospital environment. This multiple resistance could be attributed to the misuse of antibiotics, which necessitates strict prescription policies to overcome this problem.

"Antibiotic resistance is a major problem observed among most of the *P. aeruginosa* infections in the clinical setting. It can also be seen from these results that *P. aeruginosa* isolates were resistant to most of the commonly used antibiotics. *P. aeruginosa* screened had 60% resistant to gentamycin in this study, and this is similar to the low susceptibility rate reported in two different studies" (32.2% and 33%, respectively) by Samad et al. [31] and Diggle et al. [32]. The result is also in agreement with those from Spagnolo et al., (69%) [33], Langendonk et al., (77%) [34], and Shimaa et al., (73%) [35,36], but differs from those of Tuon et al., (31%) [37]. "Aminoglycosides are an essential part of the antipseudomonal chemotherapy used to treat a number of illnesses caused by *P. aeruginosa"* [36, 38]. The result also showed that ciprofloxacin inhibited the growth of only 40% of *P. aeruginosa,* and this is in contrast to a 2012 report by Akingbade et al. [26] in Abeokuta, Ogun State. Imipenem, a member of the carbapenem class, is the most effective antibiotic (70%) against the strain of *P. aeruginosa* in this study. This is in line with research conducted by Shimaa et al. [35] that found 87.2% of the *P. aeruginosa* isolates susceptible to imipenem. This study revealed the presence of blaPAO and blaOXA-50 among the three strains of MDR-*P. aeruginosa* using the PCR technique. "Many studies have reported the prevalence of blaPAO and blaOXA50 in the *P. aeruginosa* genome" [39]. "Due to the ability of *P. aeruginosa* to develop resistance to a wide variety of antibiotics through diverse molecular pathways, the emergence of MDR-*P. aeruginosa* is, in fact, a worldwide health concern.



Bla-PAO positive

bla-OXA50 positive

Fig. 3. Agarose gel pictures of PCR positive samples showing, DNA ladder on the first row, no template control along with PCR positive samples

In the present study, MDR *P. aeruginosa* showed resistance to different antibiotics, such as ampicillin, cloxacillin, erythromycin, tetracycline, cefuroxime, ceftazidime, ceftriaxone, and cefepime. It was also resistant to aminoglycosides (gentamycin) and fluoroquinolones (ciprofloxacin). Recent studies have provided detailed descriptions of each resistance mechanism and contribution to each class of antibiotics" [5,40]. It is known that some strains of *P. aeruginosa* have highly developed and acquired resistance mechanisms that enable them to withstand the majority of antibiotics. The molecular analysis of three multidrug-resistant *P. aeruginosa* shows that two of the *P. aeruginosa* possessed the two types of genes screened for (blaPAO and blaOXA-50). Similar studies have also shown a high incidence of the blaPAO and blaOXA-50 genes among MDR-*P. aeruginosa* [41,42]. It was observed that the two *P. aeruginosa* isolates (p-5 and p-7) that possessed both blaPAO and blaOXA-50 genes were resistant to penicillin, aminoglycosides, tetracyclines macrolides and carbapenems classes respectively. One of this *P. aeruginosa* isolates (P7), was also, sensitive to cephalosporin classes while the other (p-5) was resistant to cephalosporin classes. The *P. aeruginosa* isolate (p-3) that possess only blaPAO gene was resistant to penicillin, aminoglycosides, tetracyclines, cephalosporins, macrolides and carbapenems classes respectively and was sensitive to gentamycin, an aminoglycoside class. Hospital and community antibiotic stewardship need to be strengthened with proper information on combining these antibiotic classes and regulation of drug prescription, particularly in local outlets [29]. The decreased susceptibility of *P. aeruginosa* to commonly used antibiotics has also been shown in different studies [40, 5, 43,44].

5. CONCLUSION

In conclusion, this study shows that the three MDR *P. aeruginosa* that have blaPAO and blaOXA-50 beta-lactamases are resistant to penicillin, macrolide, tetracycline, fluoroquinolones, tetracycline, and carbapenems. Newer clinical approaches are needed to curtail the increasing resistance by considering the innovative integrated system in prescription and therapeutic formulation, with combined synergistic mechanism of action [28].

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of manuscripts.

CONSENT AND ETHICAL APPROVAL

The current study was approved by the ethical committee of Federal Medical Centre, Abeokuta, Nigeria. Informed consent was also given by all participants in the study.

DATA AVAILABILITY STATEMENT

The authors declare that all available data regarding the manuscript is already included within it. Any addition information regarding data of the work will be provided upon request by the corresponding author.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Qin Shugang, Wen Xiao, Min Wu. *Pseudomonas aeruginosa*; Pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. 2022;7; 199.
2. Stephanie GC, Martha V, Lasse K, Aaron MS. The environmental occurrence of *Pseudomonas aeruginosa*. Apim. 2019; 128(3):100-104.
3. Preeti P, Ragini G, Puneet Gandhi. Emergence of antibiotic resistance *Pseudomonas aeruginosa* in intensive care unit; A critical review. Genes and Diseases. 2019;6:109-119.
4. Ali Khursheed A, Bilal Ahmed A, Mohammad Saghir Khan A, Javed Musarrat A. Differential surface contact killing of pristine and low EPS *Pseudomonas aeruginosa* with Aloe vera capped hematite (α-Fe2O3) nanoparticles. Journal of Photochemistry and Photobiology B: Biology. 2018;188:146-158.
5. Obritsch MD, Fish DN, Maclaren R, Jung R. The national surveillance of antimicrobial resistance in the *Pseudomonas aeruginosa* isolates obtained from intensive care unit

patients from 1993 to 2002. Antimicrob Agents Chemother. 2004;48: 4606–4610.

6. Alnour Tang MS, Eltayib Hassan, Ahmed – Ahmed. Multi drug *Pseudomonas aeruginosa*: Medical impact, Pathogenicity, resistance mechanisms and epidemiology JSM Microbiology Sci med Central; 2017.
7. Japoni A, Alborzi A, Kalani M, Nasiri J, Hayati H, Farshad S. Susceptibility patterns and cross resistance of antibiotics against *Pseudomonas aeruginosa* isolated from burn patients in the Southof Iran. Burns. 2009; 32:343-347
8. Strateva T, Yordanov D. *Pseudomonas aeruginosa* — a phenomenon of bacterial resistance. Journal of Medical Microbiology. 2009;58:1133–1148.
9. Stephen P. Diggle, Marvin Whiteley. Microbe profile: *Pseudomonas aeruginosa*: Opportunistic pathogen and lab rat. Microbiology (Reading. 2020;166(1):30 – 33.
10. Hernandez J, Ferus MA, Hernandez M. Fingerprinting and serotyping of clinical *Pseudomonas aeruginosa* strains. FEMS Immunology Med. Micribiol. 1997;17:37-47.
11. Collin BA, Leather HL, Wingard JR, Ramphal. Evolution, incidence and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin. Infect. Dis. 2001;33(7);947-53.
12. Pollack M. *Pseudomonas aeruginosa*. In: Principles and practice of infectious diseases 5th ed. Mandell GL, Bennett JE and Dolin R (ed.), Edinburgh, Churchill Livingstone, Scotland. 2000;2310–2335.
13. Davies JC. *Pseudomonas aeruginosa* in cystic fibrosis: Pathogenesis and persistence. Paediatr Respir Rev. 2002; 3(2):128 – 34.
14. Delphine Girlich, Thierry Naas, Patrice Nordmann. Biochemical characterization of the naturally occurring oxacillinase OXA-50 OF *Pseudomonas aeruginosa*. Antimicrob. Agents Chemother. 2004;48 (6):2043 – 2048.
15. Girlich D, Naas T, Nordmann P. Biochemical characterization of the naturally occurring Oxacillinase Oxa-50 of *Pseudomonas aeruginosa*. Antimicrob. Agents Chemother. 2004;48:2043–2048.
16. Bonfiglio G, Russo G, Nicoletti G. Recent developments in carbapenems. Expert Opin. Investig. Drug. 2002;11:529–544.
17. Nicolau DP. Carbapenems: A Potent Class of Antibiotics. Expert Opin. Pharmacother. 2008;9:23–37.
18. Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-b-lactamase inhibitor combinations. Drugs. 2018;78:65–98
19. Zahedani SS, Tahmasebi H, Jahantigh M. Coexistence of virulence factors and efflux pump genes in clinical isolates of *pseudomonas aeruginosa*: Analysis of biofilm-forming strains from Iran. Int. J. Microbiol. 2021;5557361.
20. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, Sixteenth Informational Supplement; Document M100-S20; CLSI: Wayne, PA, USA; 2018.
21. EUCAST Clinical Breakpoints and Dosing. Available:https://www.eucast.org/clinical_breakpoints
22. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Paterson DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012; 18:268–281.
23. Liu B, Zheng D, Zhou S, Chen L, Yang J. Vfdb. A General classification scheme for bacterial virulence factors. Nucleic Acids Res. 2022;50:D912–D917.
24. Pulimamidi Rabindra R, Nomula R. Gel electrophoresis and it application, Gel electrophoresis - Principles and basics. In Tech ISBSN: 978-953-51-0458-2; 2012.
25. Henrici RC, Pecen TJ, Johnston JL, Tan S. The pPSU plasmids for generating DNA molecular weight markers. Scientific reports. 2017 May 26;7(1):2438.

26. Reynolds D, Kollef M. The epidemiology and pathogenesis and treatment of *pseudomonas aeruginosa* infections: An Update. Drugs. 2021;18:2117-2131.
27. Akingbade OA, Balogun SA, Ojo DA, Afolabi RO, Motayo BO, Okerentugba PO, Okonko IO. Plasmid profile analysis of multidrug resistant P. aeruginosa isolated from wound infections in South West, Nigeria. World Applied Sciences Journal. 2012;20(6):766-775.
28. Juan C, Torrens G, Gonzalez-Nicolau M, Oliver A. Diversity and regulation of intrinsic β-lactamases from non-fermenting and other Gram-negative opportunistic pathogens. FEMS Microbiol Rev. 2017;41(6):781–815.
29. Akinduti, Paul A, Onome W George, Hannah U Ohore, Olusegun Ariyo E, Samuel Popoola T, Adenike Adeleye I, Kazeem S Akinwande, Jacob Popoola O, Solomon Rotimi O, Fredrick Olufemi O, Conrad Omonhinmin A, Grace Olasehinde I. Evaluation of Efflux-Mediated Resistance and Biofilm Formation in Virulent *Pseudomonas aeruginosa* Associated with Healthcare Infections; 2023.
30. Abbas Hisham A, Amira M El-Ganiny, Hend A Kamel. Phenotypic and genotypic detection of antibiotic resistance of *Pseudomonas aeruginosa* isolated from urinary tract infections. AFR Health Sci; 2018.
31. Samad Abdul, Tanveer Ahmed, Afaq Rahim, Abdul Khalil, Iftikhar A. Antimicrobial susceptibility patternsof clinical isolates of *Pseudomonas aeruginosa* isolated from patients of respiratory tract infections in Tertiary Care Hospital. Peshawar. Pak J. Med. Sci. 2017;33(3):670 -674.
32. Diggle SP, Whiteley M. Microbe profile: *Pseudomonas aeruginosa*: Opportunistic pathogen and lab rat. Erratum in: Microbiology. 2020;167(8).
33. Spagnolo F, Trujillo M, Dennehy JJ. Why Do Antibiotics Exist? mBio. 2021;21;12 (6).
34. Langendonk Frèdi R, Daniel R. Neill, Joanne L. Fothergill. The building blocks of antimicrobial resistance in *pseudomonas aeruginosa*: Implications for current resistance-breaking therapies. Front Cell Infect Microbiol; 2021.
35. Shimaa Ghanem M, Gamal FM, Rehab Mahmoud Abd El –Baky, Nancy GF. Association between resistance, Biofilm formation and LASB gene in *Pseudomonas aeruginosa* isolated from different clinical specimens. Bullentin of Pharmaceutical Science Assiut University. 2023;10:21608.
36. Tuon FF, Dantas LR, Suss PH, Tasca Ribeiro VS. Pathogenesis of the *Pseudomonas aeruginosa* Biofilm: A Review. Pathogens. 2022;27;11(3) :300.
37. CDC. Antibiotic resistance threats in the United States. Atlanta, GA: CDC; 2013; 2016.
38. Greipel L, Fischer S, Klockgether J, et al. Molecular epidemiology of mutations in antimicrobial resistance loci of *Pseudomonas aeruginosa* isolates from airways of cystic fibrosis patients. Antimicrob Agents Chemother. 2016;60 (11):6726–6734.
39. Madaha Estelle Longla, Charlotte Mienie, Hortense Kamga Gonsu, Rhoda Nsen Bughe, Marie Christine Fonkoua, Wilfred Fon Mbacham. Whole-genome sequence of multi-drug resistant *Pseudomonas aeruginosa* strains UY1PSABAL and UY1PSABAL2 isolated from human broncho-alveolar lavage, Yaoundé, Cameroon; 2020.
40. Arya M, Arya P, Biswas D, Prasad R. The antimicrobial susceptibility pattern of the bacterial isolates from post-operative wound infections. Indian J Pathol Microbiol. 2005;48(2):266–269.
41. Du SJ, Kuo HC, Cheng CH, Fei ACY, Wei HW, Chang SK. Molecular mechanisms of ceftazidime resistance in *Pseudomonas aeruginosa* isolates from canine and human infections. Vet Med. 2010;55(4): 172–182.
42. McAulay K, Schuetz AN, Fauntleroy K. Multidrug-resistant *Pseudomonas aeruginosa* in healthcare facilities in Port-au-Prince, Haiti. J Glob Antimicrob Resist. 2021;25:60–65.
43. Algun A, Arisoy GT, Ozbakkaloglu B. The resistance of *Pseudomonas aeruginosa* strains to fuoroquinolones group of

antibiotics. Ind J Med Micro. 2004;22(2): 112–114.

44. Omar B Ahmed Detection of Antibiotic Resistance Genes in *Pseudomonas aeruginosa* by Whole Genome Sequencing ; 2004.
DOI:10.2147/IDR.S389959

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of the publisher and/or the editor(s). This publisher and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/123234